News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Features Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate Michael O'Riordan November 27, 2017